ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2459
-0,01%
Bitcoin
68.809,08
1,57%
Brent Oil
80,745
-0,07%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) Notícias

ORTX

Orchard Therapeutics (ORTX)

Orchard Therapeutics PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORTX
DataHoraFonteTítuloCódigoCompanhia
07/05/202408:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
03/05/202408:00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
20/03/202408:00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
18/03/202416:41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
14/02/202423:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
05/02/202416:39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
05/02/202409:00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
02/02/202409:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
25/01/202409:00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202419:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202418:41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202418:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202418:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202407:00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
11/12/202309:00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202318:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
30/11/202309:00GlobeNewswire Inc.Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IHNASDAQ:ORTXOrchard Therapeutics PLC
16/11/202318:45Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
13/11/202309:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORTXOrchard Therapeutics PLC
13/11/202309:00GlobeNewswire Inc.Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business AccomplishmentsNASDAQ:ORTXOrchard Therapeutics PLC
03/11/202318:11Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
26/10/202308:00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
24/10/202308:00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
05/10/202318:26Edgar (US Regulatory)Form DEFA14C - Additional information statement materials, definitiveNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202308:19IH Market NewsThursday’s Wall Street Highlights: Orchard Therapeutics, Exxon Mobil, Alphabet, Ford, and moreNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202304:35GlobeNewswire Inc.Kyowa Kirin to Acquire Orchard TherapeuticsNASDAQ:ORTXOrchard Therapeutics PLC
18/09/202308:00GlobeNewswire Inc.Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority ReviewNASDAQ:ORTXOrchard Therapeutics PLC
31/08/202308:00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023NASDAQ:ORTXOrchard Therapeutics PLC
21/08/202317:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ORTXOrchard Therapeutics PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORTX

Seu Histórico Recente

NASDAQI
HUR
ISE Cyber Security UCITS
ASE
DELTECHB1
Delta Techniki
TG
A3KWJJ
European Investment Bank
COIN
MARCOEUR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados